
Key Points
- 01Bristol Myers Squibb released first Phase 3 ADEPT data for KarXT in Alzheimer’s psychosis
- 02ADEPT-1 12-week open-label period showed a 12-point mean drop on hallucination and delusion scores
- 03ADEPT-3 52-week extension reported long-term symptom gains and defined safety profile
- 04ADEPT trials are still ongoing, with double-blind Phase 3 data remaining blinded
Bristol Myers unveils first ADEPT Phase 3 KarXT data
Bristol Myers Squibb has reported the first clinical data from its Phase 3 ADEPT program evaluating KarXT for psychosis associated with Alzheimer’s disease. On November 18, 2026, the company presented preliminary findings from the 12-week open-label period of the ADEPT-1 study and the 52-week open-label extension ADEPT-3 study in adults with Alzheimer’s disease-related psychosis.
Across both trials, treatment with KarXT, a combination of xanomeline and trospium chloride, was associated with improvements in clinician-observed hallucinations, delusions and overall disease severity. KarXT was generally well tolerated, and no new safety signals were identified in these open-label datasets, while the double-blind treatment periods in the ADEPT program remain blinded and ongoing.
ADEPT-1: 12-week open-label symptom and safety outcomes
In the ADEPT-1 Phase 3 trial, the 12-week open-label lead-in period evaluated short-term treatment with KarXT in adults with psychosis associated with Alzheimer’s disease. Participants showed a mean reduction of 12.0 points from a baseline of 14.4 on the Neuropsychiatric Inventory-Clinician Hallucinations and Delusions (NPI-C H+D) scale, based on 266 patients.
Disease severity also improved, with a mean reduction of 1.9 points from a baseline of 4.5 on the Clinical Global Impression-Severity score in 267 participants. Treatment-emergent adverse events occurred in 56.6% of participants, serious treatment-emergent adverse events in 5.0%, and 4.4% discontinued treatment due to these events during the 12-week period.
The reported findings are descriptive and exclude individuals who were still in treatment at the time of the data cutoff.
ADEPT-3: 52-week open-label extension results
ADEPT-3 is a global, 52-week open-label extension study enrolling participants who completed ADEPT-1, ADEPT-2 or ADEPT-4. At the time of analysis, 401 participants had enrolled, and 273, or 68.1%, completed the full 52-week treatment period, with KarXT described as generally well tolerated and showing low discontinuation rates over one year.
In ADEPT-3, treatment-emergent adverse events were reported in 65.1% of participants, serious treatment-emergent adverse events in 7.7%, and 4.7% discontinued due to adverse events. Symptom measures showed a mean reduction of 5.1 points from an open-label baseline of 8.9 on the NPI-C H+D scale in 270 participants and a mean reduction of 0.8 points from a baseline of 3.4 on the Clinical Global Impression-Severity score in 277 participants.
The ADEPT-3 findings, like those from ADEPT-1, are based on descriptive analyses and do not include patients who were still receiving treatment at the data cutoff. The primary objective of ADEPT-3 is to assess long-term safety and tolerability of KarXT in this patient population.
ADEPT program scope and unmet medical need
The ADEPT-1 trial is a global, randomized, double-blind, placebo-controlled relapse-prevention study that includes a 12-week open-label KarXT lead-in followed by a 26-week double-blind randomized withdrawal period, designed to evaluate time to relapse. ADEPT-3 serves as a rollover open-label extension for participants completing ADEPT-1, ADEPT-2 or ADEPT-4, while additional ADEPT studies are assessing acute efficacy and twice-daily dosing of KarXT.
Approximately 30–50% of patients with Alzheimer’s disease experience hallucinations and delusions, yet there are currently no FDA-approved treatments specifically indicated for psychosis associated with Alzheimer’s disease. KarXT, an investigational muscarinic receptor–modulating therapy already approved as Cobenfy in the United States for schizophrenia in adults, is being developed to address this gap, with further insights expected once the blinded Phase 3 data from the ADEPT program become available.
Key Takeaways
- 01Preliminary ADEPT-1 and ADEPT-3 data show KarXT was associated with measurable improvements in hallucinations, delusions and global disease severity scores.
- 02Safety findings over both 12 and 52 weeks indicate a defined profile of treatment-emergent adverse events and relatively low discontinuation rates in these open-label phases.
- 03The ADEPT program’s ongoing double-blind components will be pivotal for determining KarXT’s efficacy and relapse-prevention potential beyond these initial descriptive results.
- 04Given the absence of FDA-approved therapies for Alzheimer’s disease psychosis, KarXT’s development targets a substantial unmet need in a large patient subgroup.
- 05KarXT’s existing approval as Cobenfy for schizophrenia in adults underscores prior clinical experience with the mechanism as it is tested in Alzheimer’s-related psychosis.
References
- https://finance.yahoo.com/healthcare/articles/bristol-myers-squibb-presents-first-141000533.html?.tsrc=rss
- https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Presents-First-Clinical-Data-from-Two-Phase-3-Studies-in-the-ADEPT-Program-Evaluating-KarXT-for-Psychosis-Associated-with-Alzheimers-Disease/default.aspx
- https://ca.investing.com/news/stock-market-news/bristol-myers-squibb-shares-preliminary-karxt-trial-data-93CH-4967241
- https://de.investing.com/news/company-news/bristol-myers-squibb-legt-vorlaufige-phase3studiendaten-zu-karxt-vor-93CH-3775587